Well, its a combination of the new device being more efficient (no powder left behind) and the supposed more aggressive approach towards driving A1C down.

From the conference calls, it appears physicians were scared to try and drive the A1C down to due to concerns over hypoglycemia events, which are common when attempting to drive the A1C down too low with existing rapid acting insulins.

Not knowing the exact parameters, and what-ifs, is concering.